GRONINGEN, NETHERLANDS (30 September 2024) – VAR2 Pharmaceuticals ApS (‘VAR2 Pharma’) has received regulatory approval for their first-in-human Phase 0 clinical trial. In this study, the safety, tolerability, and biodistribution of two zirconium-89 labeled single-chain variable Fragments (scFvs) will be evaluated using PET/CT molecular imaging. The Danish company VAR2 Pharma is collaborating with TRACER, a […]
Our team is attending ESMO 2024 in Barcelona! VARCT Dx’s CSO, Mette Ørskov Agerbæk and VAR2 Pharma’s COO Frederico Pimenta will be there and are looking forward to catching up on the most recent developments in oncology. Come meet us at our poster #218P on Sunday to hear more about our latest work on using […]
The development of cancer is accompanied by a change in the composition of a sugar molecule called chondroitin sulfate. This sugar molecule becomes unusually long and heavily sulfated. For years, VAR2 has pursued the development of cancer therapeutics targeting this secondary modification called oncofetal chondroitin sulfate. But until recently, the known difficulties in generating antibodies […]
The development of CTC-derived models specific to PDAC has remained challenging due to the limited number of CTCs retrieved from patients’ samples. In work led by our collaborators, we demonstrated that our proprietary recombinant VAR2CSA, which specifically binds oncofetal chondroitin sulfate, retrieved more live CTCs than single antibodies for traditional CTC biomarkers (EpCAM, CD7, […]
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.